StockNews.AI

Aktis Oncology Announces Pricing of its Upsized Initial Public Offering

StockNews.AI • 3 days

LLYBACJPM
High Materiality9/10

Information

BOSTON, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Aktis Oncology, Inc. (“Aktis”), a clinical-stage oncology ...

Original source

AI Summary

Aktis Oncology announces an upsized IPO of 17.65 million shares. Shares are priced at $18.00, expected gross proceeds at $318 million. AKTS will begin trading on Nasdaq on January 9, 2026. A 30-day option for underwriters may increase shares by 2.65 million. The offering is aimed at enhancing capital for oncology advancements.

Sentiment Rationale

The successful IPO could lead to increased investor confidence and capital for expansion, similar to past biotech IPOs that saw growth post-offering due to additional funding for innovative projects.

Trading Thesis

Initial price movement will likely occur around IPO launch; investor sentiment may stabilize post-implementation of growth strategies.

Market-Moving

  • AKTS could experience high volatility on IPO debut.
  • Potential for large institutional investment following successful IPO.
  • High interest in oncology markets may raise AKTS’s profile.
  • Positive investor sentiment could drive share price post-IPO.
  • Expected use of proceeds may enhance AKTS's development capabilities dramatically.

Key Facts

  • Aktis Oncology announces an upsized IPO of 17.65 million shares.
  • Shares are priced at $18.00, expected gross proceeds at $318 million.
  • AKTS will begin trading on Nasdaq on January 9, 2026.
  • A 30-day option for underwriters may increase shares by 2.65 million.
  • The offering is aimed at enhancing capital for oncology advancements.

Companies Mentioned

  • LLY (LLY)
  • BAC (BAC)
  • JPM (JPM)

Corporate Developments

The IPO process and the capital influx increase AKTS's potential for successful project advancement, significantly impacting market perception and investor interest.

Aktis Oncology Announces Pricing of Upsized Initial Public Offering

BOSTON, January 8, 2026 – Aktis Oncology, Inc. (NASDAQ: AKTS), a pioneering clinical-stage oncology company, has set the pricing for its upsized initial public offering (IPO) of 17,650,000 shares of common stock at $18.00 per share. The offering aims to raise approximately $318.0 million before deducting underwriting discounts and expenses, marking a significant step in its mission to provide targeted radiopharmaceuticals to broader patient populations.

Details of the IPO

The underwriters have been granted a 30-day option to purchase an additional 2,647,500 shares at the same price, aiming to enhance the offering's total proceeds. All shares in this offering are being issued by Aktis. The public trading of Aktis' common stock is anticipated to commence on the Nasdaq Global Select Market under the ticker symbol AKTS on January 9, 2026. The offering is expected to conclude on January 12, 2026, contingent upon customary closing conditions.

Underwriters and Registration

Prominent financial institutions are leading the offering as joint book-running managers, including:

  • J.P. Morgan
  • BofA Securities
  • Leerink Partners
  • TD Cowen

A registration statement on Form S-1 (File No. 333-292283) has been filed with the Securities and Exchange Commission (SEC) and was declared effective as of January 8, 2026. The offering is being conducted solely through a prospectus, which will be available on the SEC’s website.

About Aktis Oncology

Aktis Oncology focuses on enhancing the capabilities of targeted radiopharmaceuticals to reach larger patient demographics, especially those overlooked by current treatments. Its leading pipeline initiative targets Nectin-4, a miniprotein radioconjugate designed for use against various tumor types.

Founded by MPM BioImpact, Aktis has developed its proprietary platform that precisely delivers the tumor-destructive properties of radioisotopes while minimizing collateral damage to healthy tissues. This innovative approach promotes efficient penetration and retention of therapy in cancer cells.

Moreover, Aktis has forged a strategic collaboration with Eli Lilly and Company to develop groundbreaking radioconjugates utilizing its miniprotein platform beyond its proprietary pipeline.

Contact Information

For media inquiries, please contact:

Sean Leous
ICR Healthcare
Phone: (646) 866-4012
Email: Sean.Leous@icrhealthcare.com

For investor relations, please reach out to:

Peter Vozzo
ICR Healthcare
Phone: (443) 213-0505
Email: Peter.Vozzo@icrhealthcare.com

Related News